EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6-Reference-Cited by-同舟云学术

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6

Published:2016-12-22 Issue:2 Volume:116 Page:175-185
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Wu Yi-Long,Sequist Lecia V,Hu Cheng-Ping,Feng Jifeng,Lu Shun,Huang Yunchao,Li Wei,Hou Mei,Schuler Martin,Mok Tony,Yamamoto Nobuyuki,O'Byrne Kenneth,Hirsh Vera,Gibson Neil,Massey Dan,Kim Miyoung,Yang James Chih-Hsin

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2016420.pdf

Reference34 articles.

1. Aung KL, Donald E, Ellison G, Bujac S, Fletcher L, Cantarini M, Brady G, Orr M, Clack G, Ranson M, Dive C, Hughes A (2014) Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system. J Mol Diagn 16 (3): 343–349.

2. Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J (2009) Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 27 (16): 2653–2659.

3. Board RE, Williams VS, Knight L, Shaw J, Greystoke A, Ranson M, Dive C, Blackhall FH, Hughes A (2008) Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer. Ann NY Acad Sci 1137: 98–107.

4. Brevet M, Johnson ML, Azzoli CG, Ladanyi M (2011) Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 73 (1): 96–102.

5. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, Walker J, Dearden S, Webster A, Milenkova T, McCormack R (2014a) Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 9 (9): 1345–1353.

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidermal growth factor receptor-mutated lung carcinomas with insufficient response to epidermal growth factor receptor inhibitors;Future Oncology;2024-09-04

2. Drug development and evidence for lung cancer targeted therapy in Eastern Asia;The Lancet Regional Health - Western Pacific;2024-08

3. Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC;Clinical Lung Cancer;2024-08

4. Application of liquid biopsy in lung cancer management;Indian Journal of Pathology and Microbiology;2024-07

5. Accurate Early Detection and EGFR Mutation Status Prediction of Lung Cancer Using Plasma cfDNA Coverage Patterns: A Proof-of-Concept Study;Biomolecules;2024-06-17